Proteoglycan Mimetics for Wound Healing and Angiogenesis

ChangeBridge: Patent Apps - Therapeutics (A61P)

Detected March 27th, 2026

Summary

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

View original document View source feed page

What changed

This document is a publication of a new patent application (US20260083852A1) by the USPTO. The application, filed on November 17, 2025, by inventors including Alyssa Panitch and others, describes novel proteoglycan mimetics. These mimetics are designed to act as pro-angiogenic scaffolds for tissue regeneration, protect collagen matrices from degradation, and promote angiogenesis to accelerate wound healing, particularly in the context of ischemic conditions and post-angioplasty procedures.

This patent application does not impose immediate regulatory obligations on entities. However, it signals potential future developments in therapeutic approaches for wound healing and vascular repair. Companies involved in drug development, medical device manufacturing, or healthcare provision in these areas should be aware of this innovation as it may influence future product development, research directions, and intellectual property landscapes. No compliance actions are required at this stage.

Source document (simplified)

← USPTO Patent Applications

PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR

Application US20260083852A1 Kind: A1 Mar 26, 2026

Inventors

Alyssa PANITCH, Emily Michelle MISNICK, Jenny B. LIN, Kit S. LAM, Ruiwu LIU, Dake HAO, Aijun WANG

Abstract

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).